Bayer Corporation

Miles Inc.

Bayer Pharmaceuticals Corporation

Aicuris Gmbh + Co. Kg.

Michael A Shearer

Rajiv Nayar

Wei Wang

Milton B Dobkin

George B Dove

Kris P Antonsen

Margaret Caudle

Neville M Concessio

A stable pharmaceutical preparation comprising Human interleukin-2 or a variant thereof and a stabilizing amount of histidine. A preferred formulation includes glycine and sucrose and a variant of IL-2 having a single mutation, N88R. The preferred formulation is in lyophilized form which, on reconstitution with an aqueous diluent, results in a solution having a pH ranging from about 5.0 to 6.5.

Stabilized interleukin 2

The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e.g., antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.

Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations

Soluble, intermediate length alcohols (C.sub.4 -C.sub.10) in aqueous solutions at low pH (4.0-7.0) can be used as virucidal agents for therapeutic biologically active protein preparations. Treatment with the alcohols is especially useful for proteins having activity not adversely affected by low pH.

Use of intermediate length alcohols as virucidal agents in solutions of

Growing community of inventors

Fairfield, CA, United States of America

Michael A Shearer